Skip to content
2000
image of Transverse Comparison of Clinical Characteristics and Prognostic Factors in HIV-Infected Patients with Cytomegalovirus Encephalitis in Guangdong, China

Abstract

Introduction

Cytomegalovirus encephalitis (CME) is one of the serious opportunistic complications in human immunodeficiency virus (HIV)-infected patients, characterized by rapid onset, poor prognosis, and high mortality. Until now, there has been limited comprehensive research on the clinical and prognostic characteristics of HIV/CME patients reported in China.

Methods

We conducted a retrospective study of 43 patients diagnosed with CME among individuals infected with HIV from 2015 to 2023 at Guangzhou Eighth People’s Hospital. Among them, 27 patients had a favorable prognosis, while 16 patients had an unfavorable prognosis (which includes death, treatment ineffectiveness, or aggravated condition), as determined by clinical diagnosis. The clinical symptoms and laboratory examination data for the two groups were analyzed. Multivariate analysis and a nomogram were developed using statistical variables.

Results

HIV/CME patients with an unfavorable prognosis exhibited more consciousness disorders and nuchal rigidity than those with a favorable prognosis. There were no significant differences between the two groups in terms of clinical characteristics, such as hemiparalysis, meningeal irritation, cerebrospinal fluid (CSF) pressure, and other relevant factors. In the CSF, the chloride (Cl) level was significantly higher in HIV/CME patients with a favorable prognosis, whereas the Cytomegalovirus (CMV)-DNA levels showed the opposite trend. A multivariate analysis of fever, nuchal rigidity, consciousness disorder, and CSF CMV-DNA can be used to predict prognosis in HIV/CME patients, with a C-index of 0.83 (95% CI: 0.64–1.00). The log CSF CMV-DNA copies/mL emerged as an independent risk factor for prognosis. High CSF CMV-DNA (≥300,000 copies/mL) indicated an unfavorable prognosis. This study is the first to propose a prognostic threshold for CSF CMV-DNA (≥300,000 copies/mL) and develop a nomogram that integrates clinical and laboratory features for risk prediction in HIV/CME patients in China.

Discussion

The findings highlight that CSF CMV-DNA ≥ 300,000 copies/mL, along with neurological symptoms such as consciousness disorder and nuchal rigidity, are significant predictors of unfavorable prognosis in HIV/ CME patients. The constructed nomogram offers a clinically useful tool for early risk stratification, which may aid in timely therapeutic decision-making.

Conclusion

HIV/CME patients with an unfavorable prognosis showed more obvious signs and symptoms of central nervous system infection, lower CSF Cl levels, and higher CSF CMV-DNA compared to patients with a favorable prognosis. Recognizing these indicators early and administering timely antiviral therapy before the disease progresses to CME are of great value in improving the survival rate of patients. Our findings extend beyond existing international studies by providing novel prognostic evidence in a Chinese cohort and offering a practical predictive tool for clinical risk stratification.

© 2026 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/chr/10.2174/011570162X397729251115050310
2026-01-22
2026-01-29

  • From This Site

    /content/journals/chr/10.2174/011570162X397729251115050310
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Maschke M. Kastrup O. Diener H.C. CNS manifestations of cytomegalovirus infections: Diagnosis and treatment. CNS Drugs 2002 16 5 303 315 10.2165/00023210‑200216050‑00003 11994020
    [Google Scholar]
  2. Springer K.L. Weinberg A. Cytomegalovirus infection in the era of HAART: Fewer reactivations and more immunity. J. Antimicrob. Chemother. 2004 54 3 582 586 10.1093/jac/dkh396 15282241
    [Google Scholar]
  3. Arribas J.R. Storch G.A. Clifford D.B. Tselis A.C. Cytomegalovirus encephalitis. Ann. Intern. Med. 1996 125 7 577 587 10.7326/0003‑4819‑125‑7‑199610010‑00008 8815757
    [Google Scholar]
  4. Griffiths P. Cytomegalovirus infection of the central nervous system. Herpes 2004 11 Suppl. 2 95A 104A 15319096
    [Google Scholar]
  5. Acosta E. Bowlin T. Brooks J. Advances in the development of therapeutics for cytomegalovirus infections. J. Infect. Dis. 2020 221 Suppl. 1 S32 S44 10.1093/infdis/jiz493 32134483
    [Google Scholar]
  6. Kofteridis D.P. Karabekios S. Repa A. A case of human immunodeficiency virus infection disclosed by Cytomegalovirus encephalitis. Int. J. Infect. Dis. 2007 11 4 373 375 10.1016/j.ijid.2006.11.001 17331780
    [Google Scholar]
  7. Robinson-Papp J. Simpson D.M. Neuromuscular diseases associated with HIV‐1 infection. Muscle Nerve 2009 40 6 1043 1053 10.1002/mus.21465 19771594
    [Google Scholar]
  8. Yang R. Zhang H. Xiong Y. Molecular diagnosis of central nervous system opportunistic infections and mortality in HIV-infected adults in Central China. AIDS Res. Ther. 2017 14 1 24 10.1186/s12981‑017‑0150‑2 28469695
    [Google Scholar]
  9. Jiang B. Su R. Zhang D. Gao L. Ma P. Lu W. Prevalence and associated factors of HIV and CMV co-infection in Tianjin, China. J. AIDS Clin. Res. 2018 9 5 10.4172/2155‑6113.1000767
    [Google Scholar]
  10. Zhao M. Zhuo C. Li Q. Liu L. Cytomegalovirus (CMV) infection in HIV/AIDS patients and diagnostic values of CMV-DNA detection across different sample types. Ann. Palliat. Med. 2020 9 5 2710 2715 10.21037/apm‑20‑1352 32819135
    [Google Scholar]
  11. Cinque P. Vago L. Terreni M.R. Diagnosis of cytomegalovirus infection of the nervous system in AIDS by polymerase chain reaction analysis of cerebrospinal fluid. Scand. J. Infect. Dis. Suppl. 1995 99 92 94 8668949
    [Google Scholar]
  12. Arribas J.R. Clifford D.B. Fichtenbaum C.J. Commins D.L. Powderly W.G. Storch G.A. Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. J. Infect. Dis. 1995 172 2 527 531 10.1093/infdis/172.2.527 7622897
    [Google Scholar]
  13. Wei F. Wang X. Liu L. Characterization of HIV type 1 env gene in cerebrospinal fluid and blood of infected Chinese patients. AIDS Res. Hum. Retroviruses 2011 27 7 793 796 10.1089/aid.2010.0369 21366426
    [Google Scholar]
  14. Spector S.A. Hsia K. Crager M. Pilcher M. Cabral S. Stempien M.J. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J. Virol. 1999 73 8 7027 7030 10.1128/JVI.73.8.7027‑7030.1999 10400803
    [Google Scholar]
  15. Bossolasco S. Calori G. Moretti F. Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy. Clin. Infect. Dis. 2005 40 5 738 744 10.1086/427698 15714422
    [Google Scholar]
  16. Lupia T. Milia M.G. Atzori C. Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. AIDS 2020 34 3 373 380 10.1097/QAD.0000000000002442 31764071
    [Google Scholar]
  17. Shen Y. Li T. Interpretation of “Chinese Guidelines for the Diagnosis and Treatment of HIV/AIDS (2024 Edition)”. Chin. J. Prev. Med 2025 26 2 129 132
    [Google Scholar]
  18. Lenfant T. L’Honneur A.S. Ranque B. Neurological complications of varicella zoster virus reactivation: Prognosis, diagnosis, and treatment of 72 patients with positive PCR in the cerebrospinal fluid. Brain Behav. 2022 12 2 2455 10.1002/brb3.2455 35040287
    [Google Scholar]
  19. Delamarre L. Gollion C. Grouteau G. COVID-19–associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J. Neurol. Neurosurg. Psychiatry 2020 91 9 1004 1006 10.1136/jnnp‑2020‑323678 32651243
    [Google Scholar]
  20. Valencia JC Alejandria M Salamat MS It is not always tuberculosis: cytomegalovirus polyradiculopathy and encephalitis in two Filipino men with advanced HIV infection. Open Forum Infect Dis. 2018 5 Suppl 1 S138 S139 10.1093/ofid/ofy210.362 30411030
    [Google Scholar]
  21. Zhao T. Xu X.L. Nie J.M. Establishment of a novel scoring model for mortality risk prediction in HIV-infected patients with cryptococcal meningitis. BMC Infect. Dis. 2021 21 1 786 10.1186/s12879‑021‑06417‑9 34376147
    [Google Scholar]
  22. Huang J. Chen B. Value of CSF‐Cl, CSF‐GS, CSF‐MALB, and CSF‐ADA in differential diagnosis of secondary hydrocephalus. Contrast Media Mol. Imaging 2022 2022 1 6742795 10.1155/2022/6742795 35685670
    [Google Scholar]
  23. Huang Y. Zou J. Zhang K. Prediction of hospital discharge outcome from changes in cerebrospinal fluid/serum albumin quotient and cerebrospinal fluid lactate dehydrogenase in patients with cryptococcal meningitis. Future Microbiol. 2022 17 4 223 233 10.2217/fmb‑2021‑0272 34905957
    [Google Scholar]
  24. Hakyemez I.N. Erdem H. Beraud G. Prediction of unfavorable outcomes in Cryptococcal meningitis: Results of the multicenter Infectious Diseases International Research Initiative (ID-IRI) cryptococcal meningitis study. Eur. J. Clin. Microbiol. Infect. Dis. 2018 37 7 1231 1240 10.1007/s10096‑017‑3142‑1 29218468
    [Google Scholar]
  25. Wu L. Xiao J. Song Y. Gao G. Zhao H. The clinical characteristics and outcome of Cryptococcal meningitis with AIDS in a tertiary hospital in China: An observational cohort study. BMC Infect. Dis. 2020 20 1 912 10.1186/s12879‑020‑05661‑9 33261581
    [Google Scholar]
  26. Fang X. Lu Y. Fu Y. Cerebrospinal fluid chloride is associated with disease activity of relapsing–remitting multiple sclerosis: A retrospective cohort study. Brain Sci. 2023 13 6 924 10.3390/brainsci13060924 37371400
    [Google Scholar]
  27. Tan Q.C. Zhang J. Xing X.W. Tian C.L. Huang X.S. Yu S. Significance of chloride contents in cerebrospinal fluid and plasma and their ratio in early diagnosis and differential diagnosis of central nervous system infections. Med J Chin People’s Lib Army 2014 39 401 405 10.11855/j.issn.0577‑7402.2014.05.15
    [Google Scholar]
  28. Emery V.C. Sabin C.A. Cope A.V. Gor D. Hassan-Walker A.F. Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000 355 9220 2032 2036 10.1016/S0140‑6736(00)02350‑3 10885354
    [Google Scholar]
  29. Atabani S.F. Smith C. Atkinson C. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am. J. Transplant. 2012 12 9 2457 2464 10.1111/j.1600‑6143.2012.04087.x 22594993
    [Google Scholar]
  30. Lee K.Y. Yoo B.W. Ahn S.S. Predictors of mortality in autoimmune disease patients with concurrent cytomegalovirus infections detected by quantitative real-time PCR. PLoS One 2017 12 7 0181590 10.1371/journal.pone.0181590 28742877
    [Google Scholar]
  31. Bigliano P. Calcagno A. Lucchini A. The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. Antivir. Ther. 2018 23 5 451 456 10.3851/IMP3221 29372886
    [Google Scholar]
  32. Yang X. Zhou S. Chang Z. Nanopore targeted sequencing-based diagnosis of central nervous system infections in HIV-infected patients. Ann. Clin. Microbiol. Antimicrob. 2024 23 1 22 10.1186/s12941‑024‑00682‑7 38424544
    [Google Scholar]
  33. Zhang Z. Reece M.D. Roa S. The identification of intact HIV proviral DNA from human cerebrospinal fluid. Neurotherapeutics 2024 21 4 00373 10.1016/j.neurot.2024.e00373 38749843
    [Google Scholar]
  34. Liu Q. Tao W. Yang H. Wu Y. Yu Q. Liu M. Association of high ratio of CSF/Plasma HIV-1 RNA with central nervous system co-infection in HIV-1-positive treatment-naive patients. Brain Sci. 2022 12 6 791 10.3390/brainsci12060791 35741676
    [Google Scholar]
  35. Barday Z. Manning K. Freercks R. Retrospective Review of ART Regimens in HIV-Positive to HIV-Positive Kidney Transplant Recipients. Kidney Int. Rep. 2022 Sep 7 9 2039 2046 10.1016/j.ekir.2022.06.013 36090493
    [Google Scholar]
  36. Desta A.A. Kidane K.M. Woldegebriel A.G. Level of Adherence and Associated Factors Among HIV-Infected Patients on Antiretroviral Therapy in Northern Ethiopia: Retrospective Analysis. Patient Prefer. Adherence 2020 Sep 3 14 1585 1594 10.2147/PPA.S268395 32943850
    [Google Scholar]
  37. Yang X Zhou S Chang Z Nanopore targeted sequencing-based diagnosis of central nervous system infections in HIV-infected patients. Ann Clin Microbiol Antimicrob 2024 Jan 30 23 1 22 10.1186/s12941‑024‑00682‑7 38291477
    [Google Scholar]
  38. Chakraborty A. Qato D. Antiretroviral therapy adherence among treatment-naive individuals in the US. AIDS Behav. 2019
    [Google Scholar]
  39. Zhu Y. Zhao W. Yang X. Metagenomic next-generation sequencing for identification of central nervous system pathogens in HIV-infected patients. Front. Microbiol. 2022 Nov 15 13 1055996 10.3389/fmicb.2022.1055996 36458193
    [Google Scholar]
/content/journals/chr/10.2174/011570162X397729251115050310
Loading
Transverse Comparison of Clinical Characteristics and Prognostic Factors in HIV-Infected Patients with Cytomegalovirus Encephalitis in Guangdong, China
Bentham Science Publishers ; https://doi.org/10.2174/011570162X397729251115050310
/content/journals/chr/10.2174/011570162X397729251115050310
/content/journals/chr/10.2174/011570162X397729251115050310
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: antiviral therapy ; CSF CMV-DNA ; HIV ; cytomegalovirus ; prognosis ; encephalitis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test